Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has received orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its herpetic oncolytic virus MVR-C5252. The designation is for the drug’s use in treating malignant glioma.

Drug Details
MVR-C5252, developed in-house on Immvira’s OvPENS platform, is an oncolytic virus product designed specifically for the treatment of glioma. The product is genetically engineered to selectively kill malignant glial cells while ensuring safety and promoting an immune response within the tumor microenvironment. The drug is currently being prepared for a Phase I clinical study in the United States.

Company Background
Founded in 2015, Immvira has three oncolytic virus therapies currently under development, with a total of five clinical studies either in Phase I or Phase II in China and the US.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry